Get the Stockscreener App
2.82
1.40%
-0.04
After Hours:
2.84
0.02
+0.71%
Galectin Therapeutics Inc stock is traded at $2.82, with a volume of 65,306.
It is down -1.40% in the last 24 hours and up +13.71% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$2.86
Open:
$2.84
24h Volume:
65,306
Relative Volume:
0.11
Market Cap:
$178.48M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-3.863
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
-1.05%
1M Performance:
+13.71%
6M Performance:
+129.27%
1Y Performance:
+8.88%
1-Day Range:
$2.8102
$2.865
1-Week Range:
$2.54
$3.18
52-Week Range:
$0.726
$3.9035
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.82 | 181.01M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics Inc. Stock Analysis and ForecastFree Trend-Following Techniques - Autocar Professional
What drives Galectin Therapeutics Inc. stock priceRapidly growing investment returns - jammulinksnews.com
What analysts say about Galectin Therapeutics Inc. stockAccelerated wealth building - jammulinksnews.com
Is Galectin Therapeutics Inc. a good long term investmentAccelerated wealth building - jammulinksnews.com
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Director’s Bold Move: Major Stock Purchase at Galectin Therapeutics! - TipRanks
Freeman buys Galectin therapeutics (GALT) stock worth $14,495 - Investing.com Australia
Freeman buys Galectin therapeutics (GALT) stock worth $14,495 By Investing.com - Investing.com Nigeria
What makes Galectin Therapeutics Inc. stock price move sharplyMarket Ready Callouts - Newser
Why Galectin Therapeutics Inc. stock attracts strong analyst attentionLow Volatility High Yield Stocks - Newser
Why Did Galectin Therapeutics (GALT) Soar 14.04%? - AInvest
How Galectin Therapeutics Inc. stock performs during market volatilityFree Discussion Group - Newser
Galectin Therapeutics (NASDAQ:GALT) Share Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics announces new $10 million credit line from Richard Uihlein - MSN
Galectin Therapeutics Secures $10M Credit Line for Growth - The Globe and Mail
Galectin Therapeutics secures $10 million credit line from board chairman By Investing.com - Investing.com South Africa
Galectin Therapeutics secures $10 million credit line from board chairman - Investing.com Australia
Galectin Therapeutics Inc. announced that it expects to receive $10 million in funding - MarketScreener
Galectin Therapeutics Secures Additional $10 million Credit Line - MarketScreener
ALVO 6-K: Alvotech discloses Ivers-Lee Group acquisition | GALT SEC FilingForm 8-K - Stock Titan
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 - TradingView
Board Chairman Injects $10M Into Galectin's MASH Treatment Program: Extended Funding Through 2026 - Stock Titan
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics Inc.'s (NASDAQ:GALT) stock price dropped 13% last week; individual investors would not be happy - simplywall.st
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
What is HC Wainwright's Estimate for GALT Q2 Earnings? - MarketBeat
Equities Analysts Issue Forecasts for GALT Q2 Earnings - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Holdings Lifted by Wealth Enhancement Advisory Services LLC - Defense World
Galectin Therapeutics (NASDAQ:GALT) Now Covered by Analysts at HC Wainwright - Defense World
Galectin Therapeutics Soars 22% Amid Technical Puzzles and Retail Surge - AInvest
Galectin Therapeutics stock rating initiated at buy by H.C. Wainwright - Investing.com Nigeria
Analyst Forecast For Galectin Therapeutics Inc (NASDAQ: GALT) - Stocksregister
Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainw - GuruFocus
HC Wainwright Initiates Coverage on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
HC Wainwright & Co. Initiates Coverage with Buy Rating on GALT | - GuruFocus
Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainwright | GALT Stock News - GuruFocus
Transcript : Galectin Therapeutics Inc.Special Call - MarketScreener
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):